The Vitiligo Research Foundation (VRF) is seeing the massive opportunity in collecting cheap Longitudinal Data as opposed to costly Big Data in order to expedite R&D in rare diseases, using standard healthcare and bioinformatics tools.
Conventional wisdom dictates that data analytics can make typically $1.4 billion drug development faster and cheaper. Big Data deploys sophisticated analytics to parse huge quatities of data from many disparate sources across the healthcare ecosystem to discover patterns that could be useful in problem solving.
The major problem with the current Big Data mega-trend, one that is dominating media casts and conferences nowadays, is that there is not enough data to crunch in a field of more than 7,000 rare diseases. An only slightly lesser problem is that, even if there was enough Big Data on rare diseases, it would be made up of millions of loosely related disease data snapshots, like a movie reel where each frame is technically correct but has no real relation to the surrounding frames.
Via Chatu Jayadewa